Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
May 17, 2022
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting
April 28, 2022
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
April 26, 2022
Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies
April 22, 2022
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
March 31, 2022
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team
March 21, 2022
Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update
March 18, 2022
Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer
February 28, 2022
Displaying 1 - 10 of 11